Archives

New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease

Individuals with metabolic syndrome are at an increased risk of developing chronic kidney disease (CKD) or accelerating the progression of pre-existing CKD. Further, such individuals are predisposed to developing diabetes mellitus, increasing their susceptibility to diabetic kidney disease (DKD). Current DKD treatments have expanded to include renin-angiotensin-aldosterone system (RAAS) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal […]

With 60,000+ members, SheMed raises €43 million to advance personalised women’s healthcare in the UK

SheMed, London’s female-founded HealthTech company changing how women access personalised healthcare, today announced it has raised €43 million to further develop its innovative health platform and advance new breakthroughs for preemptive healthcare. The new funding will be used to expand SheMed’s UK operations, scaling its medical and technology teams, strengthening clinical infrastructure and enhancing its […]

Blood Thinners & Anti-Obesity Shots Dominate Medicare Drug Spending

Blood Thinners & Anti-Obesity Shots Dominate Medicare Drug Spending From diabetes injectables to blockbuster blood thinners, a handful of drugs account for a sizable share of Medicare’s pharmacy bill. This visualization, via Visual Capitalist’s Pallavi Rao, ranks the most common drugs by total Medicare spending in 2023, sourced from Centers for Medicare & Medicaid Services It tracks every […]

Novo Nordisk A/S (NVO): A Bull Case Theory 

We came across a bullish thesis on Novo Nordisk A/S on The Analyst’s Journal’s Substack by A_Capital. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S’s share was trading at $56.72 as of October 15th. NVO’s trailing and forward P/E were 14.98 and 14.08, respectively according to Yahoo Finance. Novo Nordisk A/S represents a compelling long-term growth […]

The Stupidest Thing in American Health Care? Failing to Tackle Obesity Early.

It takes a very particular kind of political brainworm to look at a country where nearly half the population is obese, where Medicare and Medicaid hemorrhage cash treating diabetes, heart disease, stroke, and cancer — and say: let’s not pay for the medicine that actually fixes the root problem. And yet, here we are. GLP-1 […]